Comparison of pulmonary involvement due to COVID-19 infection in patients with ankylosing spondylitis using sulfasalazine and biologic agents

Year 2022, Volume: 3 Issue: 1, 55 - 60, 24.03.2022

Murat Doğan , Aysel Kocagül Çelikbaş , Nurcan Baykam , Ayşe Gülşen Doğan , Derya Yapar

https://doi.org/10.47582/jompac.1074753

Abstract

Objectives: The aim of this study is to examine the lung involvement caused by the SARS CoV-2 factor in patients diagnosed with ankylosing spondylitis using sulfasalazine and biological drugs.
Material and Method: File systems of patients with RT-PCR positive AS diagnosis who have undergone COVID-19 were retrospectively reviewed. Patients with a diagnosis of AS were divided into two groups as those using sulfasalazine and biological agents. Thoracic computed tomography (CT) results of the patients were divided into mild, moderate, severe, bilateral or unilateral. The data were also compared between the patient and control groups.
Results: Of the 58 patients included in the study, 26 were receiving biological agent and 32 were receiving sulfsalazine. Of the patients using DMARD, 17 were receiving adalimumab, 4 etanercept, 2 golimumab, 2 certolizumab, and 1 patient infliximab. Thirteen patients in the AS group had lung involvement due to SARS CoV-2 on thorax computed tomography. It was seen that patients, 9 men and 4 women, were hospitalized due to COVID-19. In 10 patients, involvement due to COVID-19 was found in both lungs.
Conclusion: It is not yet known whether immunomodulatory treatments used in autoimmune and inflammatory rheumatic diseases will affect the course of COVID-19 positively or negatively. In this study, COVID-19 progressed with mild symptoms in patients diagnosed with AS using sulfasalazine and biological agents.

Keywords

Ankilozan spondilit, Covid-19, sulfasalazin, DMARD

Ankilozan spondilit tanılı sulfasalazin ve biyolojik ajan kullanan hastaların COVID-19 enfeksiyonuna bağlı akciğer tutulumlarının karşılaştırılması

Abstract

Amaç: Bu çalışmanın amacı, ankilozan spondilit tanılı sülfasalazin ve biyolojik ilaç kullanan hastalarda SARS CoV-2 faktörünün neden olduğu akciğer tutulumunu incelemek.
Gereç ve Yöntem: COVID-19 geçirmiş RT-PCR pozitif AS tanısı olan ve en az bir yıldır hastanemizde takibi olan hastaların dosya sistemleri retrospektif olarak gözden geçirildi. AS tanısı alan hastalar sülfasalazin ve biyolojik ajan kullananlar olarak iki gruba ayrıldı. Hastaların toraks bilgisayarlı tomografi (BT) sonuçları hafif, orta, şiddetli, iki taraflı ve tek taraflı olarak ayrıldı. Veriler ayrıca hasta ve kontrol grupları arasında karşılaştırıldı.
Bulgular: Çalışmaya alınan 58 hastanın 26’sı biyolojik ajan, 32’si sülfasalazin alıyordu. DMARD kullanan hastalardan 17’si adalimumab, 4’ü etanercept, 2’si golimumab, 2’si sertolizumab ve 1’i infliximab kullanıyordu. AS grubundaki 13 hastada toraks bilgisayarlı tomografisinde SARS CoV-2 nedeniyle akciğer tutulumu vardı. 9’u erkek, 4’ü kadın olan hastaların COVID-19 nedeniyle hastaneye yatırıldığı görüldü. 10 hastada her iki akciğerde de COVID-19’a bağlı tutulum saptandı.
Sonuç: otoimmün ve inflamatuar romatizmal hastalıklarda kullanılan immünomodülatör tedavilerin COVID-19 seyrini olumlu ya da olumsuz etkileyeceği henüz bilinmemektedir. Bizim çalışmamızda sulfasalazin ve biyolojik ajan kullanan AS tanılı hastalarda COVID-19 hafif semptomlarla seyretmiştir.

Keywords

Ankilozan spondilit, Covid-19, sulfasalazin, DMARDs

References

• World Health Organization. Novel coronavirus situation report-2. January 22,2020. https://reliefweb.int/sites/reliefweb.int/files/resources/20200122-sitrep-2-2019-ncov.pdf (Accessed on 04/02/2021).
• Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr 2020; 63.4: 119.
• T.C Sağlık Bakanlığı COVID-19 Rehberi. Accessed at: https://COVID19.saglik.gov.tr/Eklenti/39551/0/COVID-19rehberigenelbilgiler epidemiyolojivetanipdf on 04/02/2021
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiolooy of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London), 2020; 30251-8.
• Huang C, Wang Y, Li X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475–81.
• Zhao H, Shen D, Zhou H, Liu J, Sheng C. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol 2020; 19: 383-4.
• Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief, 8 April 2020, World Health Organization (2020). https://apps.who.int/iris/bitstream/handle/10665/331713/WHO-2019-nCoV-Sci_Brief-POC_immunodiagnostics-2020.1-eng.pdf (Accessed on 04/02/ 2021).
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
• Sangha O. Epidemiology of rheumatic diseases. Rheumatology 2000; 39: 3-12.
• Atzeni F, Bendtzen K, Bobbio-Pallavicini F, et al. Infections and treatment of patients with rheumatic diseases. Clinical and experimental rheumatology 2008; 26: 67-73.
• Gianfrancesco M, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020.
• Razumova IY, Godzenko AA, Vorob’eva OK, Guseva IA. Uveitis in spondyloarthritis patients and its association with HLA-B27 histocompatibility antigen: prospective study. Vestn Oftalmol 2016; 132: 4-9.
• Quismorio FP Jr. Pulmonary involvement in ankylosing spondylitis. Curr Opin Pulm 2006; 12: 342–5
• Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014; 27: CD004800
• Lequerré T, Farran É, Ménard JF, et al. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers. Joint Bone Spine 2015; 82: 330-7.
• Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev 2020; 19: 102523.
• EULAR COVID-19 Database. 18.05.2020 ed. https: //www.eular.org/eular_COVID19_database.cfm
• Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020.
• Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmunity Rev 2020; 102575.
• Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–8.
• Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis 2021; 80: 18.
• Lee JM, Lee SJ. Olfactory and gustatory dysfunction in a COVID-19 patient with ankylosing spondylitis treated with etanercept: case report. J Korean Med Sci 2020; 35: 201.
• Brito CA, Paiva JG, Pimentel FN, Guimarães RS, Moreira MR. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis 2021; 80: 61.
• Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis 2020; 79: 1251-2.
• McInnes IB. COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis 2020; 79: 551–2.
• Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020; 39: 2055-62.
• Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic: Versiyon 3. Arthritis Rheumatol 2021; 73: 1-12.
• Cron RQ, Chatham WW. The rheumatologist’s role in COVID-19. J Rheumatol 2020; 47: 639–42.